1. Home
  2. FIHL vs PVLA Comparison

FIHL vs PVLA Comparison

Compare FIHL & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fidelis Insurance Holdings Limited

FIHL

Fidelis Insurance Holdings Limited

N/A

Current Price

$18.74

Market Cap

2.0B

Sector

N/A

ML Signal

N/A

Logo Palvella Therapeutics Inc.

PVLA

Palvella Therapeutics Inc.

N/A

Current Price

$135.66

Market Cap

1.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
FIHL
PVLA
Founded
2014
2015
Country
Bermuda
United States
Employees
N/A
14
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.9B
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
FIHL
PVLA
Price
$18.74
$135.66
Analyst Decision
Hold
Strong Buy
Analyst Count
7
16
Target Price
$22.50
$161.13
AVG Volume (30 Days)
436.2K
320.3K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
3.21%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.34
N/A
Revenue Next Year
$7.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.56
$18.23
52 Week High
$20.50
$151.18

Technical Indicators

Market Signals
Indicator
FIHL
PVLA
Relative Strength Index (RSI) 41.59 66.08
Support Level $18.56 $76.95
Resistance Level $19.05 $151.18
Average True Range (ATR) 0.53 9.87
MACD -0.12 1.41
Stochastic Oscillator 26.23 77.74

Price Performance

Historical Comparison
FIHL
PVLA

About FIHL Fidelis Insurance Holdings Limited

Fidelis Insurance Holdings Ltd is a specialty insurer that leverages strategic partnerships to offer tailored insurance solutions. The company classifies its business into two segments, Insurance and Reinsurance. A majority of its revenue is generated from the Insurance segment, which comprises a portfolio of property, marine, aviation and aerospace, political risk, violence and terror, energy, cyber, and other insurance risks. The Reinsurance segment consists of an actively managed property reinsurance book, providing reinsurance and a limited amount of retrocession coverage across the world on a proportional or excess-of-loss basis. Geographically, the company derives its key revenue from the United Kingdom, followed by Bermuda and the Republic of Ireland.

About PVLA Palvella Therapeutics Inc.

Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.

Share on Social Networks: